Literature DB >> 3132573

Increasing dextrose concentrations in total parenteral nutrition (TPN) causes alterations in hepatic morphology and plasma levels of insulin and glucagon in rats.

S Li1, M S Nussbaum, D Teague, C L Gapen, R Dayal, J E Fischer.   

Abstract

Hepatic steatosis is an ongoing problem in total parenteral nutrition (TPN). The etiology of this deranged hepatic morphology is unclear, but lack of enteral stimulation and excess carbohydrate calories have been suggested as altering the intestinal hormone profile. In this study, adult male Sprague-Dawley rats (n = 28) received internal jugular catheters: group 1 (n = 7) received saline (3 cc/hr) and chow ad libitum; groups 2, 3, and 4 (n = 7) received 15, 20, and 25% dextrose-base TPN solutions, respectively, in quantities matching the caloric intake of paired ad libitum animals. At 7 days portal and peripheral venous blood samples were drawn for insulin and glucagon radioimmunoassay, and livers were removed for histologic examination and determination of total hepatic lipid content. Portal and peripheral insulin levels rose in a linear fashion with increasing dextrose concentration. Lipid content increased with elevated portal venous insulin/glucagon ratio in groups 3 and 4. Periportal fatty infiltration increased with increasing dextrose concentrations. The results suggest that the liver's response to altered portal insulin/glucagon ratio may play an important role in changes of hepatic morphology associated with TPN.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3132573     DOI: 10.1016/0022-4804(88)90095-9

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  8 in total

1.  Fish oil-based injectable lipid emulsions containing medium-chain triglycerides or added α-tocopherol offer anti-inflammatory benefits in a murine model of parenteral nutrition-induced liver injury.

Authors:  Meredith A Baker; Bennet S Cho; Lorenzo Anez-Bustillos; Duy T Dao; Amy Pan; Alison A O'Loughlin; Zachary M Lans; Paul D Mitchell; Vania Nosé; Kathleen M Gura; Mark Puder; Gillian L Fell
Journal:  Am J Clin Nutr       Date:  2019-04-01       Impact factor: 7.045

2.  Taurine and cholestasis associated to TPN. Experimental study in rabbit model.

Authors:  J M Moran; J Salas; F Botello; E Macià; V Climent
Journal:  Pediatr Surg Int       Date:  2005-10-21       Impact factor: 1.827

Review 3.  Abnormal liver function tests in the parenteral nutrition fed patient.

Authors:  S M Gabe; A Culkin
Journal:  Frontline Gastroenterol       Date:  2010-06-15

4.  Cholecystokinin (CCK) secretion in patients with severe short bowel syndrome (SSBS).

Authors:  P R Ling; M Sheikh; P Boyce; M Keane-Ellison; A Thibault; P Burke; S Freedman; B R Bistrian
Journal:  Dig Dis Sci       Date:  2001-04       Impact factor: 3.199

Review 5.  Prevention and Treatment of Intestinal Failure-Associated Liver Disease in Children.

Authors:  Lorenzo Norsa; Emanuele Nicastro; Angelo Di Giorgio; Florence Lacaille; Lorenzo D'Antiga
Journal:  Nutrients       Date:  2018-05-24       Impact factor: 5.717

Review 6.  New insights into intestinal failure-associated liver disease in adults: A comprehensive review of the literature.

Authors:  Fotios S Fousekis; Ioannis V Mitselos; Dimitrios K Christodoulou
Journal:  Saudi J Gastroenterol       Date:  2021 Jan-Feb       Impact factor: 2.485

7.  Parenteral nutrition associated cholestasis is earlier, more prolonged and severe in small for gestational age compared with appropriate for gestational age very low birth weight infants.

Authors:  Soon Min Lee; Ran Namgung; Min Soo Park; Ho Sun Eun; Nam Hyo Kim; Kook In Park; Chul Lee
Journal:  Yonsei Med J       Date:  2013-07       Impact factor: 2.759

8.  Parenteral nutrition-induced cholestasis in neonates: where does the problem lie?

Authors:  Kheira Jolin-Dahel; Emanuela Ferretti; Carolina Montiveros; Renee Grenon; Nick Barrowman; Carolina Jimenez-Rivera
Journal:  Gastroenterol Res Pract       Date:  2013-11-14       Impact factor: 2.260

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.